Brokers Set Expectations for MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at Brookline Capital Management issued their Q1 2026 earnings per share estimates for Monopar Therapeutics in a research note issued to investors on Thursday, September 25th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.81) per share for the quarter. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS and Q4 2026 earnings at ($0.83) EPS.

Several other analysts have also issued reports on MNPR. Lake Street Capital started coverage on Monopar Therapeutics in a research note on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 target price for the company. BTIG Research increased their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday. Chardan Capital increased their price objective on Monopar Therapeutics from $60.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright started coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They set a “buy” rating and a $70.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics currently has an average rating of “Buy” and a consensus target price of $82.33.

Monopar Therapeutics Price Performance

Shares of MNPR opened at $76.63 on Monday. The firm has a market cap of $472.81 million, a P/E ratio of -23.01 and a beta of 1.20. The stock has a 50 day simple moving average of $44.46 and a two-hundred day simple moving average of $39.50. Monopar Therapeutics has a 1 year low of $4.50 and a 1 year high of $79.80.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12.

Insiders Place Their Bets

In related news, CEO Chandler Robinson sold 16,800 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer owned 73,472 shares in the company, valued at $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $356,160.00. Following the transaction, the director owned 11,486 shares of the company’s stock, valued at approximately $459,440. This represents a 43.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 592,733 shares of company stock worth $36,700,227 in the last ninety days. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $34,000. AlphaQuest LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $44,000. JPMorgan Chase & Co. lifted its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics during the second quarter worth about $80,000. Finally, New York State Common Retirement Fund purchased a new stake in Monopar Therapeutics in the second quarter worth about $104,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.